Crabb David P

Glaucoma Home Monitoring Using a Tablet-Based Visual Field Test (Eyecatcher): An Assessment of Accuracy and Adherence Over 6 Months.

Home monitoring of VFs is viable for some patients and may provide clinically useful data.

Portable Perimetry Using Eye-Tracking on a Tablet Computer-A Feasibility Assessment.

Portable perimetry using an inexpensive eye-tracker and a tablet computer is feasible, although possible means of improvement are suggested.

Visual Field Outcomes from the Multicenter, Randomized Controlled Laser in Glaucoma and Ocular Hypertension Trial (LiGHT).

A slightly larger proportion of ocular hypertensive and glaucoma patients treated first with medical therapy underwent rapid VF progression compared with those treated first with SLT.

A Comparison between the Compass Fundus Perimeter and the Humphrey Field Analyzer.

Relative diagnostic precision of the 2 devices is equivalent. Test-retest variability of MS for CMP was better than for HFA.

Are Patient Self-Reported Outcome Measures Sensitive Enough to Be Used as End Points in Clinical Trials?: Evidence from the United Kingdom Glaucoma Treatment Study.

Average change in PROMs on health-related and vision-related quality of life was similar for the treatment and placebo groups in the UKGTS.

Five-Year Visual Field Outcomes of the HORIZON Trial.

CS-HMS has a significant effect on VF preservation in glaucoma patients compared with CS alone, reducing the proportion of fast progressors.

Improving the Feasibility of Glaucoma Clinical Trials Using Trend-Based Visual Field Progression Endpoints.

The feasibility of future glaucoma clinical trials can be substantially improved by evaluating differences in the rate of visual field change between groups.

Does Glaucoma Alter Eye Movements When Viewing Images of Natural Scenes? A Between-Eye Study.

Eye movements are altered by visual field loss, and these changes are related to changes in clinical measures. Eye movements recorded while passively viewing images could potentially be used as biomarkers for visual field damage.

Policy-Driven, Multimodal Deep Learning for Predicting Visual Fields from the Optic Disc and OCT Imaging.

The multimodal, policy DL model performed the best; it provided explainable maps of its confidence in fusing data from single modalities and provides a pathway for probing the structure-function relationship in glaucoma.

Does eye examination order for standard automated perimetry matter?

Statistically significant perimetric fatigue effects manifest on average in the second eye tested in routine clinics using Humphrey Field Analyzer SITA examinations.

Evaluating the Impact of Uveitis on Visual Field Progression Using Large-Scale Real-World Data.

Our analysis suggests that VF loss occurs faster in glaucoma patients with uveitis than those without uveitis.

A Scoping Review of Quality of Life Questionnaires in Glaucoma Patients.

Wide variability among questionnaires used to determine vision related QoL in glaucoma and in the responses elicited was identified.

Improving the Power of Glaucoma Neuroprotection Trials Using Existing Visual Field Data.

Selecting patients with low intertest variability can significantly improve the power and reduce the sample size needed in a trial.

Hierarchical Censored Bayesian Analysis of Visual Field Progression.

Bayesian hierarchical models improved the detection of VF progression. Accounting for censoring improves the precision of the estimates, but minimal effect is provided by accounting for heteroskedasticity.

Revisiting the Drasdo Model: Implications for Structure-Function Analysis of the Macular Region.

The Drasdo model can effectively account for AL assuming geometric scaling. Method 2 should be used for structure-function analyses.

Improving Visual Field Examination of the Macula Using Structural Information.

Binary responses can be modeled to incorporate detailed structural information from macular OCT into visual field testing, improving overall speed and accuracy in poor responders.

Relationship between Intraocular Pressure Fluctuation and Visual Field Progression Rates in the United Kingdom Glaucoma Treatment Study.

No evidence supports that either diurnal or long-term IOP fluctuation, as measured in clinical practice, are independent factors for glaucoma progression; other aspects of IOP, including mean IOP and peak IOP, may be more informative.

Patient-reported Outcomes, Functional Assessment, and Utility Values in Glaucoma.

Standardizing and improving methods of patient-centered data collection and analysis in glaucoma studies are imperative.

Visual Field Endpoints for Neuroprotective Trials: A Case for AI-Driven Patient Enrichment.

An AI model can identify high-risk patients to substantially reduce the number of patients needed or study duration required to meet clinical trial endpoints.

Example of monitoring measurements in a virtual eye clinic using 'big data'.

Using 'big data' collected in the standard glaucoma care service, we found that patients attending a GMS have equivalent outcomes on the VF test.

Two-Year Visual Field Outcomes of the Treatment of Advanced Glaucoma Study (TAGS).

There was no significant difference in the average RoP at 2 years.

Estimating the Distribution of True Rates of Visual Field Progression in Glaucoma.

The distribution of "true" RoPs can be estimated with an exGaussian-LMM, improving model accuracy.

A New Graphical Tool for Assessing Visual Field Progression in Clinical Populations.

Hedgehog Plots provide a tool for visualizing VF progression in groups of patients and can be used potentially to prioritize monitoring resources.

Validating Trend-Based End Points for Neuroprotection Trials in Glaucoma.

The trend-based methods can efficiently detect treatment effects defined by long-term FDA-compatible progression.

The Human Touch: Using a Webcam to Autonomously Monitor Compliance During Visual Field Assessments.

Inexpensive, autonomous measures of task compliance are associated with measurement error in visual field assessments, in terms of both the overall reliability of a test and failures to respond on particular trials ("lapses").

Relationship Between Intraocular Pressure and the True Rate of Functional and Structural Progression in the United Kingdom Glaucoma Treatment Study.

VF appeared to deteriorate at a faster rate than structural measurements. However, this could be explained by the floor-effect from nonfunctional tissue. IOP induced a similar acceleration in RoP per mm Hg increase.

Do Additional Testing Locations Improve the Detection of Macular Perimetric Defects in Glaucoma?

Visual field examinations with additional macular locations can improve the detection of macular defects in GON modestly without loss of specificity when appropriate criteria are selected.

Does the Visual Field Improve After Initiation of Intraocular Pressure Lowering in the United Kingdom Glaucoma Treatment Study?

Initial short-term VF changes in the treatment and placebo arms of UKGTS were the same.

Spatial Summation in the Glaucomatous Macula: A Link With Retinal Ganglion Cell Damage.

Macular sensitivity loss in glaucoma is better described by a model in which RA changes with RGC loss. Structural measurements have limited dynamic range.

Improving the Accuracy and Speed of Visual Field Testing in Glaucoma With Structural Information and Deep Learning.

DL structure-function predictions from clinically available OCT scans can improve perimetry in glaucoma patients.

Systematic and Random Mapping Errors in Structure - Function Analysis of the Macula.

Rotating the perimetric grid to match the fovea-disc axis is not recommended. Fixation eccentricity and instability should be taken into account for structure-function analyses.

Six-Year Rate of Visual Field Progression in the Laser in Glaucoma and Ocular Hypertension Trial.

First-line SLT was more effective than drops at preserving VF.

On the Feasibility of Accelerating Glaucoma Clinical Trials Using Portable Perimetry.

Home VF assessments, despite poorer reliability than current reference standard ("in-clinic") devices, would allow faster or greater detection of glaucoma progression via an increased frequency of testing, and could reduce the sample size requirements of future clinical trials.

Eyecatcher 3.0 - Validating the Use of "Smart Glasses" as a Low-Cost, Portable Method of Assessing Visual Fields.

Smart glasses may provide a feasible means of VFs home-monitoring.

Validating and Updating the OHTS-EGPS Model Predicting 5-year Glaucoma Risk among Ocular Hypertension Patients Using Electronic Records.

We performed an external validation of the OHTS-EGPS model in a large English population.

A Practical Framework for the Integration of Structural Data Into Perimetric Examinations.

Structurally enhanced perimetric examination can significantly improve test time in healthy subjects and can be delivered through a user-friendly interface. Further testing will need to assess feasibility and performance of S-ZEST in patients with glaucoma.

Archetypes of Binocular Visual Field Loss and Their Impact on Vision-Related Quality of Life in Glaucoma Patients.

Twelve visual field loss archetypes clarify how specific defect patterns impact glaucoma patients' vision-related quality of life. This helps clinicians and patients better understand the functional consequences of different visual field defects.

Comparing the Rate of Retinal Nerve Fiber Layer and Visual Field Loss as Outcomes in Glaucoma Trials.

Using realistic modeling of structure-function progression and test-retest data, MD progression showed higher statistical power cpRFNL as an outcome measure for clinical trials.

Refining Visual Field Trend Progression Criteria in Glaucoma: Impact of Significance Thresholds and Test Frequency.

A substantial proportion of apparent progression at the established P < 0.05 threshold may be falsely positive.

Association of Systemic Calcium Channel Blocker Use with Visual Field Progression in a Large Real-World Cohort from Glaucoma Clinics.

Calcium channel blocker use was statistically significantly associated with a slower rate of VF deterioration after multivariable adjustment.

Author Response: The Distribution of True Visual Field Progression Rates in Glaucoma.

Measures of multiple deprivation and visual field loss in glaucoma clinics in England: lessons from big data.

Large-scale VF data from clinics indicates that glaucoma severity at presentation to English HES is associated with levels of multiple deprivation.

Reclaiming the Periphery: Automated Kinetic Perimetry for Measuring Peripheral Visual Fields in Patients With Glaucoma.

Patients with similar central visual field loss can have strikingly different peripheral visual fields, and therefore measuring the peripheral visual field may add clinically valuable information.

Patterns of Binocular Visual Field Loss Derived from Large-Scale Patient Data from Glaucoma Clinics.

In a clinical population of patients with measurable VF loss in both eyes, superior-only binocular VF loss is more common than inferior-only loss.

More Accurate Modeling of Visual Field Progression in Glaucoma: ANSWERS.

ANSWERS is more sensitive to detect VF progression and predicts future VF loss better than linear regression of MD and PoPLR, especially over short observation periods. (http://www.isrctn.com number, ISRCTN96423140.).

Impact of superior and inferior visual field loss on hazard detection in a computer-based driving test.

In this study, simulated VF defects impaired the ability to detect driving hazards relative to participants' normal performances, with superior defects having more impact than inferior defects.

Time to abandon over-simplified surrogates of ocular perfusion pressure in glaucoma research.

Measurement precision in a series of visual fields acquired by the standard and fast versions of the Swedish interactive thresholding algorithm: analysis of large-scale data from clinics.

Although SITA Standard is a more precise testing algorithm than SITA Fast at lower VF sensitivities, it is unlikely to make a sizeable difference to improving the time to detect VF progression.